SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Sponsor
Fayoum University
Study ID
NCT04853615
Status
Unknown

Conditions

  • SGLT2i Kideny Protection Against Contrast in Diabetic Kidney

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast Acute Kidney Injury in diabetic kidney disease.

Key Dates

Start date
Jul 1, 2021
Status verified
Apr 2021
Primary completion
Jul 1, 2024
Completion
Aug 1, 2024

Study Design

Enrollment
800 participants (estimated)

Arms

  • Arm: Group 1
    1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
  • Arm: Group 2
    2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
  • Arm: Group 3
    3rd group will receive the SGLT2i empagliflosin 25 mg once daily
  • Arm: Group 4
    4thwill receive allopurinol and empagliflosin.

Primary Outcome Measure

SGLT2i proves protective effect [ Time Frame: 72hours after contrast ]

Central Contacts